5-iodouridine-5'-O-[(phosphonomethyl)phosphonic acid] ditriethylamine salt

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-iodouridine-5'-O-[(phosphonomethyl)phosphonic acid] ditriethylamine salt
• 英文别名: 5-iodouridine-5’-O-[(phosphonomethyl)phosphonic acid] ditriethylene；5-Iodouridine5'-Methylenediphosphate TriethylammoniumSalt；N,N-diethylethanamine;[[(2R,3S,4R,5R)-3,4-dihydroxy-5-(5-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid
• 化学式: 2C₆H₁₅N*C₁₀H₁₅IN₂O₁₁P₂
• 分子量: 730.472
• InChiKey: BRVDASGBMDNJFO-OYUVGMAPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.55
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  206
• 氢给体数：
  6
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  α,β-CH2-5-I-UDP 在 乙酸–三乙胺 作用下， 以 乙腈 为溶剂， 以2 mg的产率得到5-iodouridine-5'-O-[(phosphonomethyl)phosphonic acid] ditriethylamine salt
  参考文献：
  名称：

  Pyrimidine Ribonucleotides with Enhanced Selectivity as P2Y₆ Receptor Agonists: Novel 4-Alkyloxyimino, (S)-Methanocarba, and 5′-Triphosphate γ-Ester Modifications

  摘要：

  The P2Y(6) receptor is a cytoprotective G-protein-coupled receptor (GPCR) activated by UDP (EC50 = 0.30 mu M). We compared and combined modifications to enhance P2Y(6) receptor agonist selectivity, including ribose ring constraint, 5-iodo and 4-alkyloxyimino modifications, and phosphate modifications such as alpha,beta-methylene and extension of the terminal phosphate group into gamma-esters of UTP analogues. The conformationally constrained (S)-methanocarba-UDP is a full agonist (EC50 = 0.042 mu M). 4-Methoxyimino modification of pyrimidine enhanced P2Y(6), preserved P2Y(2) and P2Y(4), and abolished P2Y(14) receptor potency, in the appropriate nucleotide. N-4-Benzyloxy-CDP (15, MRS2964) and N-4-methoxy-Cp3U Cp3U (12, MRS2957) were potent, selective P2Y(6) receptor agonists (EC50 of 0.026 and 0.012 mu M, respectively). A hydrophobic binding region near the nucleobase was explored with receptor modeling and docking. UTP-gamma-aryl and cycloalkyl phosphoesters displayed only intermediate P2Y(6) receptor potency but had enhanced stability in acid and cell membranes. UTP-glucose was inactive, but its (S)-methanocarba analogue and N-4-methoxycytidine 5'-triphospho-gamma-[1]glucose were active (EC50 of 2.47 and 0.18 mu M, respectively). Thus, the potency, selectivity, and stability of pyrimidine nucleotides as P2Y(6) receptor agonists may be enhanced by modest structural changes.

  DOI：

  10.1021/jm100287t

文献信息

• Structure–Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5′-Nucleotidase (CD73) Inhibitors
  作者：Anna Junker、Christian Renn、Clemens Dobelmann、Vigneshwaran Namasivayam、Shanu Jain、Karolina Losenkova、Heikki Irjala、Sierra Duca、Ramachandran Balasubramanian、Saibal Chakraborty、Frederik Börgel、Herbert Zimmermann、Gennady G. Yegutkin、Christa E. Müller、Kenneth A. Jacobson

  DOI：10.1021/acs.jmedchem.9b00164

  日期：2019.4.11

  Cluster of differentiation 73 (CD73) converts adenosine 5'-monophosphate to immunosuppressive adenosine, and its inhibition was proposed as a new strategy for cancer treatment. We synthesized 5'- O-[(phosphonomethyl)phosphonic acid] derivatives of purine and pyrimidine nucleosides, which represent nucleoside diphosphate analogues, and compared their CD73 inhibitory potencies. In the adenine series

  分化簇73（CD73）将5'-单磷酸腺苷转化为免疫抑制腺苷，其抑制作用被提出作为一种新的癌症治疗策略。我们合成了嘌呤和嘧啶核苷的5'-O-[（膦酰基甲基）膦酸]衍生物，它们代表核苷二磷酸类似物，并比较了它们对CD73的抑制作用。在腺嘌呤系列中，大多数核糖修饰和1-deaza和3-deaza都是有害的，但可以容忍7-deaza。耐受尿嘧啶被N3-甲基取代，但不能被较大的基团或2-硫代取代。不容许1，2-二膦酰基-乙基修饰。N4-（芳基）烷氧基-胞嘧啶衍生物，特别是具有庞大的苄氧基取代基的化合物，显示出增强的效力。最有效的抑制剂是5' -5-氟尿苷（4l），N4-苯甲酰基胞苷（7f），N4- [O-（4-苄氧基）]胞苷（9h）和N4- [O的O-[（膦酰基甲基）膦酸]衍生物-（4-萘-2-基甲氧基）]-胞苷（9e）（在人CD73上Ki值为5-10 nM）。在两种尿苷二磷酸激活的P2Y受体亚型上
• Pyrimidine Ribonucleotides with Enhanced Selectivity as P2Y₆ Receptor Agonists: Novel 4-Alkyloxyimino, (S)-Methanocarba, and 5′-Triphosphate γ-Ester Modifications
  作者：Hiroshi Maruoka、Matthew O. Barrett、Hyojin Ko、Dilip K. Tosh、Artem Melman、Lauren E. Burianek、Ramachandran Balasubramanian、Barkin Berk、Stefano Costanzi、T. Kendall Harden、Kenneth A. Jacobson

  DOI：10.1021/jm100287t

  日期：2010.6.10

  The P2Y(6) receptor is a cytoprotective G-protein-coupled receptor (GPCR) activated by UDP (EC50 = 0.30 mu M). We compared and combined modifications to enhance P2Y(6) receptor agonist selectivity, including ribose ring constraint, 5-iodo and 4-alkyloxyimino modifications, and phosphate modifications such as alpha,beta-methylene and extension of the terminal phosphate group into gamma-esters of UTP analogues. The conformationally constrained (S)-methanocarba-UDP is a full agonist (EC50 = 0.042 mu M). 4-Methoxyimino modification of pyrimidine enhanced P2Y(6), preserved P2Y(2) and P2Y(4), and abolished P2Y(14) receptor potency, in the appropriate nucleotide. N-4-Benzyloxy-CDP (15, MRS2964) and N-4-methoxy-Cp3U Cp3U (12, MRS2957) were potent, selective P2Y(6) receptor agonists (EC50 of 0.026 and 0.012 mu M, respectively). A hydrophobic binding region near the nucleobase was explored with receptor modeling and docking. UTP-gamma-aryl and cycloalkyl phosphoesters displayed only intermediate P2Y(6) receptor potency but had enhanced stability in acid and cell membranes. UTP-glucose was inactive, but its (S)-methanocarba analogue and N-4-methoxycytidine 5'-triphospho-gamma-[1]glucose were active (EC50 of 2.47 and 0.18 mu M, respectively). Thus, the potency, selectivity, and stability of pyrimidine nucleotides as P2Y(6) receptor agonists may be enhanced by modest structural changes.